Jonathon B. Cohen

8.9k citations

131 papers · 2.4k indexed · 1 hit paper · h-index 23

Impact in

Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment
Genetics top 1%
- Chronic Lymphocytic Leukemia Research

Papers in

Pathology and Forensic Medicine 102
- Lymphoma Diagnosis and Treatment 102
Genetics 49
- Chronic Lymphocytic Leukemia Research 49

Co-authors: Christopher R. Flowers Stephen M. Ansell Philippe Armand Anne Sumbul Margaret A. Shipp Irl Brian Greenwell John M. Timmerman Kazunobu Kato
Journals: Blood (50 papers)Journal of Clinical Oncology (16 papers)Hematological Oncology (9 papers)Cancer (6 papers)Blood Advances (5 papers)
Partner nations: United States Canada Italy

In The Last Decade

Jonathon B. Cohen

126 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial 2018 · 455 citations

Peers

Countries citing papers authored by Jonathon B. Cohen

Since Specialization

Citations

This map shows the geographic impact of Jonathon B. Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathon B. Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathon B. Cohen more than expected).

Fields of papers citing papers by Jonathon B. Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathon B. Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathon B. Cohen. The network helps show where Jonathon B. Cohen may publish in the future.

Co-authors

The 25 scholars most cited alongside Jonathon B. Cohen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jonathon B. Cohen Line = papers co-authored together Jonathon B. Cohen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma Blood ·Anne Beaven, Susan M. Geyer, Jonathon B. Cohen, Tycel Phillips, Travis Dockter, Priyanka A. Pophali, Gita Thanarajasingam, Gina L. Mazza, Alvaro J. Alencar, Shira Dinner, Eric D. Hsi, M.X. Welliver, Daniel A. Nikcevich, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard	2024	0
2	Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma. Journal of Clinical Oncology ·Yucai Wang, Melissa C. Larson, Anita Kumar, Brian T. Hill, David A. Bond, Brad S. Kahl, Alexey V. Danilov, Reid W. Merryman, Natalie S. Grover, Aung M. Tun, Sabarish Ayyappan, Georgios Pongas, Craig A. Portell, Javier Muñoz, Patrick M. Reagan, Muhamad Alhaj Moustafa, Priyanka A. Pophali, Irl Brian Greenwell, Jonathon B. Cohen, Peter Martin	2024	1
3	Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial EClinicalMedicine ·Jonathan W. Friedberg, Michael T. Brady, Myla Strawderman, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen, Patrick M. Reagan, Carla Casulo, SiadkowskaE., Andrea Baran, Grerk Sutamtewagul, Paul M. Barr, John P. Leonard, John M. Ashton, John Strang, Francisco Vega, Derick R. Peterson, Loretta J. Nastoupil	2024	3
4	Defining primary refractory large B-cell lymphoma Blood Advances ·Allison M. Bock, Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew J. Maurer, Amy Ayers, Brad S. Kahl, Peter Martin, Jonathon B. Cohen, Carla Casulo, Izidore S. Lossos, Umar Farooq, Sabarish Ayyappan, Rebecca Kaplan, Thomas M. Habermann, Thomas E. Witzig, Christopher R. Flowers, James R. Cerhan, Loretta J. Nastoupil, Grzegorz S. Nowakowski	2024	7
5	Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma Transplantation and Cellular Therapy ·Javier Muñoz, Ian W. Flinn, Jonathon B. Cohen, Jessica Sachs, Mituru Uyama, Ann Ranger, 葛颖倩, Francis Payumo, Rajneesh Nath, Mehdi Hamadani, Jason R. Westin, Veronika Bachanová	2023	2
6	Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma Blood ·Juan Pablo Alderuccio, Isildinha M. Reis, Jean L. Koff, Melissa C. Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M. Habermann, Peter Martin, Jennifer R. Chapman, Christopher Strouse, Brad S. Kahl, Jonathon B. Cohen, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, Izidore S. Lossos	2023	6
7	Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis Blood Advances ·Danny Luan, Gerald C. Dudgeon, Ahmed Toure, Christopher R. Flowers, Brian K. Link, Jonathan W. Friedberg, Jonathon B. Cohen, Brad S. Kahl, Izidore S. Lossos, Loretta J. Nastoupil, Matthew J. Maurer, James R. Cerhan, Peter Martin	2022	3
8	Herpes simplex virus lymphadenitis is associated with tumor reduction in a patient with chronic lymphocytic leukemia Journal of Clinical Investigation ·Andrés Chang, Anton M. Sholukh, Andreas Wieland, David L. Jaye, Mary Carrington, Meei‐Li Huang, Hong Xie, Keith R. Jerome, Pavitra Roychoudhury, Alexander L. Greninger, Jean L. Koff, Jonathon B. Cohen, David M. Koelle, Lawrence Corey, Christopher R. Flowers, Rafi Ahmed	2022	4
9	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes Blood Advances ·Alessia Castellino, Yucai Wang, Melissa C. Larson, Matthew J. Maurer, Brian K. Link, Umar Farooq, Andrew L. Feldman, Sergei Syrbu, Thomas M. Habermann, Jonas Paludo, David J. Inwards, Thomas E. Witzig, Stephen M. Ansell, Cristine Allmer, Susan L. Slager, Jonathon B. Cohen, Peter Martin, James R. Cerhan, Grzegorz S. Nowakowski	2021	13
10	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission Blood ·Mazyar Shadman, Marcelo C. Pasquini, Kwang Woo Ahn, Yue Chen, Cameron J. Turtle, Peiman Hematti, Jonathon B. Cohen, Farhad Khimani, Siddhartha Ganguly, Reid W. Merryman, Jean A. Yared, Frederick L. Locke, Nausheen Ahmed, Pashna N. Munshi, Amer Beitinjaneh, Patrick M. Reagan, Alex F. Herrera, Craig S. Sauter, Mohamed A. Kharfan‐Dabaja, Mehdi Hamadani	2021	62
11	Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial The Lancet Haematology ·Catherine Diefenbach, Fangxin Hong, Richard F. Ambinder, Jonathon B. Cohen, Michael J. Robertson, Kevin A. David, Ranjana H. Advani, Timothy S. Fenske, Stefan K. Barta, Neil Palmisiano, Jakub Svoboda, David Morgan, Reem Karmali, Elad Sharon, Howard Streicher, Brad S. Kahl, Stephen M. Ansell	2020	97
12	Is Limited-Stage Mantle Cell Lymphoma Curable and How Is It Best Managed? Hematology/Oncology Clinics of North America ·Jason T. Romancik, Jonathon B. Cohen	2020	1
13	Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood ·Matthew A. Lunning, Julie M. Vose, Loretta J. Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael Weiss, Susan O’Brien	2019	64
14	Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies Blood ·Nirav N. Shah, Amrita Krishnan, Nina Shah, John M. Burke, Jason M. Melear, Alexander I. Spira, Leslie Popplewell, Charalambos Andreadis, Saurabh Chhabra, Jeff P. Sharman, Jonathan L. Kaufman, Jonathon B. Cohen, Rubén Niesvizky, Thomas G. Martin, Clifford DiLea, N. M. Goodman, Shannon Matheny, John P. Leonard, Arturo Molina	2019	16
15	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial Journal of Clinical Oncology ·Philippe Armand, Andreas Engert, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Margaret A. Shipp, Kazunobu Kato, Anne Sumbul, Benedetto Farsaci, Stephen M. Ansell Hit paper breakdown →	2018	455
16	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy Cancer ·Irl Brian Greenwell, Ashley D. Staton, Michael J. Lee, Jeffrey M. Switchenko, Debra Saxe, Joseph Maly, Kristie A. Blum, Natalie S. Grover, Stephanie Mathews, Max J. Gordon, Alexey V. Danilov, Narendranath Epperla, Timothy S. Fenske, Mehdi Hamadani, Steven I. Park, Christopher R. Flowers, Jonathon B. Cohen	2018	34
17	Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study Blood ·Radhakrishnan Ramchandren, Michelle A. Fanale, Antonio Rueda, Philippe Armand, Marek Trněný, Tatyana Feldman, Stephen M. Ansell, Mariano Provencio, Ulrich Jaeger, Jonathon B. Cohen, Kerry J. Savage, Wolfgang Willenbacher, Mariana Sacchi, Anne Sumbul, Eva Domingo‐Doménech	2017	22
18	Surveillance Imaging during First-Remission in Follicular Lymphoma Does Not Impact Overall Survival Blood ·Р.Ф. Мустафин, 誠司浅井, Zhengjia Chen, Oscar Calzada, Michael C. Churnetski, Christopher R. Flowers, Jonathon B. Cohen	2017	7
19	GIFT4 fusokine converts leukemic B cells into immune helper cells Journal of Translational Medicine ·Jiusheng Deng, Andrea Pennati, Jonathon B. Cohen, Piet J. Van Espen, F Tomicki, Jian Wu, Christopher R. Flowers, Jacques Galipeau	2016	8
20	Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms Clinical Lymphoma Myeloma & Leukemia ·信夫寺崎, Jean L. Koff, Loretta J. Nastoupil, Jessica N. Williams, Jonathon B. Cohen, Christopher R. Flowers	2014	73

About Jonathon B. Cohen

Jonathon B. Cohen is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Neurology and Pulmonary and Respiratory Medicine, having authored 131 papers that have together received 2.4k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (102 papers), Chronic Lymphocytic Leukemia Research (49 papers), Viral-associated cancers and disorders (29 papers), CAR-T cell therapy research (29 papers), Lung Cancer Treatments and Mutations (18 papers), CNS Lymphoma Diagnosis and Treatment (16 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and Sarcoma Diagnosis and Treatment (11 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.7k citations), Genetics (725 citations), Oncology (1.6k citations), Immunology (579 citations) and Neurology (406 citations). Jonathon B. Cohen has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Christopher R. Flowers, Stephen M. Ansell, Philippe Armand, Anne Sumbul, Margaret A. Shipp, Irl Brian Greenwell, John M. Timmerman, Kazunobu Kato, Kerry J. Savage and Marek Trněný. Their work appears in journals such as Blood, Journal of Clinical Oncology, Hematological Oncology, Cancer and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact